

Table S1: Published data on the distribution of *Achromobacter* species in chronically colonized and non-chronically colonized CF patients. CC: number of chronically colonized patients. NC: number of non-chronically colonized patients. U: unknown. other species : *Achromobacter* species not yet characterized.

Reference	Countries	Nb of CF patients	CC	NC	Species involved in chronic colonization (nb of patients)	Species involved in non-chronic colonization (nb of patients)	Nb colonized patients with several species
Our study. 2021	France	181	88	93	<i>A. xylosoxidans</i> (76) <i>A. insuavis</i> (8) <i>A. mucicolens</i> (2) <i>A. marplatensis</i> (1) <i>A. genogroup 3</i> (1)	<i>A. xylosoxidans</i> (61) <i>A. insuavis</i> (15) <i>A. mucicolens</i> (4) <i>A. marplatensis</i> (5) <i>A. aegrifaciens</i> (2) <i>A. insolitus</i> (2) <i>A. genogroup 20</i> (2) <i>A. dolens</i> (4) <i>A. animicus</i> (1) <i>A. deleyi</i> (1)	4
Filipic et al. 2017 (10)	Serbia	13	6	7	<i>A. xylosoxidans</i> (5) <i>A. dolens/A. ruhlandii</i> (1)	<i>A. xylosoxidans</i> (6) <i>A. insuavis</i> (1) <i>A. marplatensis</i> (1)	1
Edwards et al. 2017 (5)	Canada	18	8	10	<i>A. xylosoxidans</i> (5) <i>A. insuavis</i> (2) <i>A. spanius</i> (1)	<i>A. xylosoxidans</i> (4) <i>A. insuavis</i> (3) <i>A. dolens</i> (2) <i>A. spanius</i> (1) <i>A. ruhlandii</i> (1)	
Gabrielaite et al. 2021 (14)	Denmark	51	32	19	<i>A. xylosoxidans</i> (31) <i>A. ruhlandii</i> (15) <i>A. insuavis</i> (12) <i>A. aegrifaciens</i> (1) other species (1)		
Gade et al. 2017 (12)	Denmark	42	20	22	<i>A. ruhlandii</i> (8) <i>A. xylosoxidans</i> (7) <i>A. insuavis</i> (5)	<i>A. xylosoxidans</i> (8) <i>A. insuavis</i> (5) <i>A. aegrifaciens</i> (2) <i>A. denitrificans</i> (1) <i>A. mucicolens</i> (1) <i>A. piechaudii</i> (1) <i>A. marpletensis</i> (1) <i>A. dolens</i> (1) <i>A. spanius</i> (1) <i>A. genogroup 19</i> (1)	
Veschetti et al. 2021 (6)	Italy	26	17	9	<i>A. xylosoxidans</i> (12) <i>A. insuavis</i> (2) <i>A. dolens</i> (1)	<i>A. aegrifaciens</i> (1) <i>A. xylosoxidans</i> (5) <i>A. insolitus</i> (1)	1

					<i>A. insolitus</i> (1) other species (1)	other species (1)	
Dupont et al. 2015 (24)	France Montpellier	13	13		<i>A. xylosoxidans</i> (10) <i>A. dolens</i> (1) <i>A. insuavis</i> (2)	<i>This study was limited to patients chronically colonized with Achromobacter</i>	
Barrado et al. 2013 (8)	Spain	14	9	5	<i>A. xylosoxidans</i> (8) <i>A. anxifer</i> (1) <i>A. deleyi</i> (1)	<i>A. xylosoxidans</i> (2) <i>A. insuavis</i> (1) <i>A. dolens</i> (1)	1
Pereira et al. 2017 (9)	Brazil	39	8	31	<i>A. xylosoxidans</i> (4) <i>A. ruhlandii</i> (4)	<i>A. xylosoxidans</i> (28) <i>A. ruhlandii</i> (5)	2
Amoureux et al. 2016 (23)	France Dijon	47	11	36	<i>A. xylosoxidans</i> (9) <i>A. insuavis</i> (2)	<i>A. xylosoxidans</i> (19) <i>A. insuavis</i> (7) <i>A. aegrifaciens</i> (7) <i>A. marplatensis</i> (7) <i>A. animicus</i> (5) <i>A. insolitus</i> (2) <i>A. mucicolens</i> (1) <i>A. spanius</i> (1) other species (3)	8
Coward et al. 2020 (4)	UK	138	U	U	<i>A. xylosoxidans</i> (95) <i>A. dolens</i> (11) <i>A. ruhlandii</i> (5) <i>A. insuavis</i> (9) <i>Achromobater</i> sp. cluster II (7) <i>A. deleyi</i> (3) <i>Achromobater</i> sp. cluster V (1) <i>A. denitrificans</i> (1) <i>A. mucicolens</i> (1) <i>A. piechaudii</i> (1) <i>A. marplatensis</i> (4)		
Coward et al. 2016 (3)	UK	96	U	U	<i>A. xylosoxidans</i> (59) <i>A. insuavis</i> 2a (10) <i>A. insuavis</i> 2b (2) <i>A. dolens</i> (8) <i>A. ruhlandii</i> (3) <i>A. marplatensis</i> (5) <i>A. genogroup 3</i> (2) <i>A. genogroup 13</i> (1) <i>A. mucicolens</i> (1) <i>Achromobater</i> sp. cluster I (1) <i>Achromobater</i> sp. cluster II (4) <i>Achromobater</i> sp. cluster III (1)		
Spilker et al. 2012 (20)	USA	341	U	U	<i>A. xylosoxidans</i> (143) <i>A. ruhlandii</i> (80) <i>A. dolens</i> (58) <i>A. insuavis</i> (15) <i>A. aegrifaciens</i> (13) <i>A. insolitus</i> (13) <i>A. genogroup 3</i> (5) <i>A. mucicolens</i> (4) <i>A. animicus</i> (3) <i>A. anxifer</i> (2) <i>A. genogroup 8</i> (2)		

					<i>A. denitrificans</i> (1) <i>A. genogroup</i> 13 (1) <i>A. spanius</i> (1)	
Voronina et al. 2017 (18)	Russia	>100 (U)	U	U	<i>A. ruhlandii</i> (57.7%) <i>A. xylooxidans</i> (35.6%) <i>A. pulmonis</i> (2.06%) <i>A. marplatensis</i> (2.06%) <i>A. mucicolens</i> (1.03%) <i>A. insuavis</i> (1.03%) <i>A. dolens</i> (1.03%)	
Rodrigues et al. 2015 (13)	Brazil	16	U	U	<i>A. xylooxidans</i> (12) <i>A. ruhlandii</i> (4) <i>A. insuavis</i> (1) <i>A. dolens</i> (1)	2
Papalia et al. 2020 (11)	Argentina	NK (41 isolates)	U	U	<i>A. xylooxidans</i> (26) <i>A. ruhlandii</i> (7) <i>A. dolens</i> (4) <i>A. insuavis</i> (2) <i>A. pulmonis</i> (1) <i>A. marplatensis</i> (1)	
Amoureux et al. 2019 (7)	France	109	U	U	<i>A. xylooxidans</i> (80) <i>A. insuavis</i> (10) <i>A. dolens</i> (4) <i>A. mucicolens</i> (4) <i>A. marplatensis</i> (3) <i>A. aegrifaciens</i> (3) <i>A. insolitus</i> (2) <i>A. pulmonis</i> (1) <i>A. deleyi</i> (1) <i>A. genogroup</i> 3 (1)	

Bibliography

1. Dumolin C, Peeters C, Ehsani E, Tahon G, De Canck E, Cnockaert M, Boon N, Vandamme P. 2020. *Achromobacter veterisilvae* sp. nov., from a mixed hydrogen-oxidizing bacteria enrichment reactor for microbial protein production. *Int J Syst Evol Microbiol* 70:530–536.
2. Spilker T, Vandamme P, LiPuma JJ. 2013. Identification and distribution of *Achromobacter* species in cystic fibrosis. *J Cyst Fibros* 12:298–301.

3. Coward A, Kenna DTD, Perry C, Martin K, Doumith M, Turton JF. 2016. Use of *nrda* gene sequence clustering to estimate the prevalence of different *Achromobacter* species among Cystic Fibrosis patients in the UK. *J Cyst Fibros* 15:479–485.
4. Coward A, Kenna DTD, Woodford N, Turton JF, Armstrong M, Auckland C, Bowler I, Burns P, Cargill J, Carroll M, Flight W, Graver M, Green H, Horner C, Jones A, Jones AM, Jones G, Mayell S, Orendi J, Perry A, Robb A, Tucker N, Waine D, Winstanley T, Withers N. 2020. Structured surveillance of *Achromobacter*, *Pandora* and *Ralstonia* species from patients in England with cystic fibrosis. *J Cyst Fibros* 19:388–393.
5. Edwards BD, Greysen-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin HR, Surette MG, Parkins MD. 2017. Prevalence and Outcomes of *Achromobacter* Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study. *J Clin Microbiol* 55:2074–2085.
6. Veschetti L, Sandri A, Patuzzo C, Melotti P, Malerba G, Lleo MMY 2021. Genomic characterization of *Achromobacter* species isolates from chronic and occasional lung infection in cystic fibrosis patients. *Microb Genomics* 7:000606.
7. Amoureux L, Sauge J, Sarret B, Lhoumeau M, Bajard A, Tetu J, Bador J, Neuwirth C, Caillon J, Cardot-Martin E, Cattoir V, Doléans-Jordheim A, Ferroni A, Guet-Revillet H, Héry-Arnaud G, Segonds C, Thomas E, Plésiat P, Vu-Thien H. 2019. Study of 109 *Achromobacter* spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of *A. xylosoxidans* belonging to ST 137. *J Cyst Fibros* 18:804–807.
8. Barrado L, Brañas P, Orellana MÁ, Martínez MT, García G, Otero JR, Chaves F. 2013. Molecular Characterization of *Achromobacter* Isolates from Cystic Fibrosis and Non-Cystic Fibrosis Patients in Madrid, Spain. *J Clin Microbiol* 51:1927–1930.

9. Pereira RHV, Leão RS, Carvalho-Assef AP, Albano RM, Rodrigues ERA, Firmida MC, Folescu TW, Plotkowski MC, Bernardo VG, Marques EA. 2017. Patterns of virulence factor expression and antimicrobial resistance in *Achromobacter xylosoxidans* and *Achromobacter ruhlandii* isolates from patients with cystic fibrosis. *Epidemiol Infect* 145:600–606.
10. Filipic B, Malesevic M, Vasiljevic Z, Lukic J, Novovic K, Kojic M, Jovcic B. 2017. Uncovering Differences in Virulence Markers Associated with *Achromobacter* Species of CF and Non-CF Origin. *Front Cell Infect Microbiol* 7:224.
11. Papalia M, Steffanowski C, Traglia G, Almuzara M, Martina P, Galanternik L, Vay C, Gutkind G, Ramírez MS, Radice M. 2020. Diversity of *Achromobacter* species recovered from patients with cystic fibrosis, in Argentina. *Rev Argent Microbiol* 52:13–18.
12. Gade SS, Nørskov-Lauritsen N, Ridderberg W. 2017. Prevalence and species distribution of *Achromobacter* sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. *J Med Microbiol* 66:686–689.
13. Rodrigues ERA, Ferreira AG, Leão RS, Leite CCF, Carvalho-Assef AP, Albano RM, Marques EA. 2015. Characterization of *Achromobacter* Species in Cystic Fibrosis Patients: Comparison of blaOXA-114 PCR Amplification, Multilocus Sequence Typing, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. *J Clin Microbiol* 53:3894–3896.
14. Gabrielaite M, Bartell JA, Nørskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, Marvig RL. 2021. Transmission and Antibiotic Resistance of *Achromobacter* in Cystic Fibrosis. *J Clin Microbiol* 59:e02911-20.

15. Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V. 2017. Clinical Outcomes Associated with *Achromobacter* Species Infection in Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 14:1412–1418.
16. Cools P, Ho E, Vranckx K, Schelstraete P, Wurth B, Franckx H, Ieven G, Van Simaey L, Van daele S, Verhulst S, De Baets F, Vaneechoutte M. 2016. Epidemic *Achromobacter xylosoxidans* strain among Belgian cystic fibrosis patients and review of literature. *BMC Microbiol* 16:122.
17. Pereira RHV, Carvalho-Assef AP, Albano RM, Folescu TW, Jones MCMF, Leão RS, Marques EA. 2011. *Achromobacter xylosoxidans*: Characterization of Strains in Brazilian Cystic Fibrosis Patients. *J Clin Microbiol* 49:3649–3651.
18. Voronina OL, Kunda MS, Ryzhova NN, Aksenova EI, Sharapova NE, Semenov AN, Amelina EL, Chuchalin AG, Gintsburg AL. 2018. On Burkholderiales order microorganisms and cystic fibrosis in Russia. *BMC Genomics* 19:74.
19. Ridderberg W, Wang M, Nørskov-Lauritsen N. 2012. Multilocus Sequence Analysis of Isolates of *Achromobacter* from Patients with Cystic Fibrosis Reveals Infecting Species Other than *Achromobacter xylosoxidans*. *J Clin Microbiol* 50:2688–2694.
20. Spilker T, Vandamme P, LiPuma JJ. 2012. A Multilocus Sequence Typing Scheme Implies Population Structure and Reveals Several Putative Novel *Achromobacter* Species. *J Clin Microbiol* 50:3010–3015.
21. Garrigos T, Neuwirth C, Chapuis A, Bador J, Amoureux L, Andre E, Barbier E, Caillon J, Cardot-Martin E, Cattoir V, Doléans-Jordheim A, Echahidi F, Ferroni A, Guet-Revillet H, Héry-Arnaud G, Lipuma J, Nørskov-Lauritsen N, Peeters C, Pierard D, Segonds C, Thomas E, Plésiat P, Vandamme P, Verroken A, Vu-Thien H. 2021. Development of a

- database for the rapid and accurate routine identification of *Achromobacter* species by matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS). *Clin Microbiol Infect* 27:126.e1-126.e5.
22. Garrigos T, Dollat M, Magallon A, Chapuis A, Varin V, Bador J, Makki N, Cremet L, Persyn E, Cardot-Martin E, Echahidi F, Peeters C, Pierard D, Vandamme P, Verroken A, Neuwirth C, Amoureux L. 2021. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones *Achromobacter xylosoxidans* ST137 and *Achromobacter ruhlandii* DES from Cystic Fibrosis Patients. *J Clin Microbiol* 59:e0094621.
 23. Amoureux L, Bador J, Bounoua Zouak F, Chapuis A, de Curraize C, Neuwirth C. 2016. Distribution of the species of *Achromobacter* in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of *A. xylosoxidans* and clonal relationships between some clinical and environmental isolates. *J Cyst Fibros* 15:486–494.
 24. Dupont C, Michon A-L, Jumas-Bilak E, Nørskov-Lauritsen N, Chiron R, Marchandin H. 2015. Inpatient diversity of *Achromobacter* spp. involved in chronic colonization of Cystic Fibrosis airways. *Infect Genet Evol* 32:214–223.